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Abstract
The last 30 years have seen a major advance in the understanding of the clinical and pathological 
heterogeneity of amyotrophic lateral sclerosis (ALS), and its overlap with frontotemporal 
dementia. Multiple, seemingly disparate biochemical pathways converge on a common clinical 
syndrome characterized by progressive loss of upper and lower motor neurons. Pathogenic themes 
in ALS include excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, 
altered energy metabolism, and most recently RNA mis-processing. The transgenic rodent, 
overexpressing mutant superoxide dismutase-1, is now only one of several models of ALS 
pathogenesis. The nematode, fruit fly and zebrafish all offer fresh insight, and the development of 
induced pluripotent stem cell-derived motor neurons holds promise for the screening of candidate 
therapeutics. The lack of useful biomarkers in ALS contributes to diagnostic delay, and the 
inability to stratify patients by prognosis may be an important factor in the failure of therapeutic 
trials. Biomarkers sensitive to disease activity might lessen reliance on clinical measures and 
survival as trial endpoints and reduce study length. Emerging proteomic markers of neuronal loss 
and glial activity in cerebrospinal fluid, a cortical signature derived from advanced structural and 
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functional MRI, and the development of more sensitive measurements of lower motor neuron 
physiology are leading a new phase of biomarker-driven therapeutic discovery.
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Introduction
There is an intense need to establish biomarkers sensitive to diagnosis, prognostic 
stratification and disease activity of ALS (Table I). The diagnosis of amyotrophic lateral 
sclerosis (ALS) currently depends upon the opinion of an experienced neurologist, and the 
exclusion of potential mimic disorders. In the context of progressive weakness, where there 
are typical upper (UMN) and lower motor neuron (LMN) signs within the same body region, 
there is little diagnostic doubt and few tangible mimics. However, such obviously mixed 
clinical signs may not be apparent at presentation (or indeed ever) for a large proportion of 
patients, who are nonetheless considered to form part of the wider syndrome of ALS (1). 
This syndrome is currently unified by the post mortem finding of cytoplasmic inclusions of 
the protein TDP-43, with the notable exception of those with mutant SOD1 gene-associated 
ALS (approximately 1% of all cases) in whom the disease is nonetheless clinically 
indistinguishable (2). The failure of multiple drugs tried for the treatment of ALS may in 
part be a function of their application relatively late in the course of the disease, given the 
average diagnostic delay of one year (3). It is not yet known when the initial pathological 
changes of ALS begin, but it seems likely that the clinical manifestations occur significantly 
downstream of what may be rapidly irreversible primary events at the cellular level. Earlier 
diagnosis would permit introduction of therapies nearer to these initiating events.
ALS is usually an apparently sporadic disorder and the insidious clinical onset involves 
symptoms common to more benign disorders, which means that a significant proportion of 
the diagnostic latency may remain inaccessible. At the time of diagnosis, however, there is 
additional value in identifying biomarkers sensitive to the recognized variation in 
progression rate. Although the median survival from symptom onset in ALS is less than 
three years, the second half of the survival curve is longer, and beyond a decade for at least 
5% of patients. The presence of relatively ‘ pure’  UMN or LMN clinical signs is associated 
with longer survival (4, 5), with the rare UMN-only variant primary lateral sclerosis 
consistently at the extreme end of long survival. However, such clinical findings cannot be 
reliably used prognostically in isolation. A quantifiable prognostic measure might also be 
used to stratify patients within clinical trials to detect meaningful benefit in the shortest time. 
Knowledge of an individual patient' s course at the time of diagnosis would facilitate 
effective care planning and resource targeting.
Finally, biomarkers sensitive to disease activity are the most needed. At present, clinical 
trials in ALS generally rely on tracheostomy-free survival, functional status such as the 
revised ALS Functional Rating Scale (ALSFRS-R), or both, as the primary outcome 
measures. Such trials are lengthy (12 – 18 months typically) and may be prohibitively 
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costly. A number of methods have been proposed to optimize and shorten such studies (6), 
but a robust, quantitative monitoring biomarker would have obvious value in this regard.
Biological themes
With the linking of familial ALS to several apparently disparate genes, it seems increasingly 
likely that ALS represents a common final endpoint. A deeper understanding of the common 
molecular pathways involved in ALS pathogenesis would facilitate the identification of 
biomarkers. Three genes linked to familial ALS in recent years, namely TARDBP, FUS and 
C9orf72, indicate a potentially pivotal role for RNA mis-processing in the pathogenesis of 
ALS (see Al-Chalabi et al., companion paper). Downstream of these events, cellular 
biological studies over the last two decades have led to the development of multiple 
interconnected pathogenic themes in ALS (7).
Excitotoxicity
Excitotoxicity encapsulates a process of neuronal death ultimately mediated by cellular 
calcium influx, triggered via excessive stimulation of receptors for glutamate. The finding of 
raised levels of glutamate in the CSF in ALS (8), with a sensitivity of only 40% in a later 
study and correlation with disease severity (9), provides support for this.
The astrocytic glutamate transporter EAAT2 is responsible for the clearance of synaptic 
glutamate, and its knockout in transgenic mice results in neuronal death (10). Reduced levels 
of spinal cord EAAT2 protein have been noted in end-stage rodent transgenic models of 
ALS (11,12), with abnormalities of EAAT2 protein expression demonstrable in up to 80% 
of human post mortem brain and spinal cord tissue (13). EAAT2 receptor dysfunction has 
been directly linked to mutant (but not wild-type) SOD1 in the presence of hydrogen 
peroxide (14). Overexpression of EAAT2 in mutant SOD1 transgenic mice then delayed the 
onset of motor deficits (15, 16). This role for astrocytes supports the view that motor neuron 
degeneration in ALS is not cell-autonomous. Although the exact mechanism of action is 
uncertain, the only disease-modifying drug in ALS to date, namely riluzole, appears to have 
broadly anti-glutamatergic activity (17).
Glutamate acts through inotropic (NMDA, AMPA and kainate) and metabotropic receptors 
(MGluRs), and the relative contribution of these to. ALS pathogenesis remains uncertain. 
The development of novel selective positron emission tomography (PET) ligands may 
provide clarification. It is possible that excitotoxicity arises in ALS as a result of wider 
‘ upstream’  impairments of energy metabolism in ALS so that ‘ normal’  levels of glutamate 
become toxic. There is also a body of evidence, including from in vivo neuroimaging, 
indicating an overall loss of neuronal inhibitory influence in ALS, perhaps through a 
primary interneuronal dysfunction, resulting in excitotoxicity through less balanced 
glutamatergic activity (18).
Oxidative stress
Oxidative stress arises from an alteration in the balance between the generation of reactive 
oxygen species (ROS) and their removal, together with the ability of the biological system to 
remove or repair ROS induced damage. The cumulative effect of oxidative stress in aged 
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non-replicating neurons, may be one important factor that tips the balance of homeostatic 
control mechanisms from an ability to cope with a toxic insult such as the presence of a 
disease-causing mutation, into a vicious cycle of cellular injury culminating in neuronal 
death and the onset of neurodegeneration in middle or later life. Oxidative stress causes 
structural damage (including DNA (19)) and also changes in redox-sensitive signalling 
pathways. The initial interest in the role of oxidative stress in ALS (20) was given new 
impetus with the discovery that mutations in SOD1, which encodes a major anti-oxidant 
defence protein, accounted for approximately 20% of cases of familial ALS (21). It is clear 
that oxidative stress interacts with and potentially exacerbates other pathophysiological 
processes contributing to motor neuron injury, including excitotoxicity, mitochondrial 
impairment, protein aggregation, endoplasmic reticulum stress and alterations in signalling 
from astrocytes and microglia. Several potential markers of free radical damage have been 
found in the CSF and blood from ALS patients (reviewed in (22)), and also in urine (23).
Cellular ROS are generated as by-products of aerobic metabolism, predominantly due to 
leakage of electrons from the mitochondrial respiratory chain, but with contributions from 
other intracellular enzyme systems including xanthine oxidase and cytochrome P450. ROS 
that are initially formed such as superoxide and hydrogen peroxide may undergo further 
reaction to produce more potent oxidant species including peroxynitrite and hydroxyl 
radicals. Biochemical indices of oxidative damage to proteins, lipids and DNA in excessive 
quantities compared to controls, can be found in post mortem tissue from apparently 
sporadic and SOD1 -related familial cases. Oxidative damage to RNA species has also been 
documented, adding to the evidence that alteration in mRNA processing is an important 
pathophysiological mechanism in ALS (24). Indices of oxidative damage are also present in 
cellular and murine models of SOD1 -related ALS, and interestingly the SOD1 protein itself 
appears to be particularly susceptible to oxidative post-translational modification. The recent 
development of cellular models of mutant TDP-43-related ALS indicates that the presence 
of mutant TDP-43 also provokes oxidative stress within motor neuronal cell lines (25).
Sources of oxidative stress in ALS have been investigated most thoroughly in mutant SOD1 
(mSOD1) models, where several aberrant oxidative reactions have been proposed. However, 
enzymatically inactive SOD1, depleted of copper loading, is still capable of causing motor 
neuron degeneration, and mSOD1 may cause oxidative stress by mechanisms beyond its 
own catalytic activity (26). mSOD1 within microglia increases superoxide production by 
NADPH oxidase (Nox) enzymes. SOD1 stabilizes Rac1-GTP in the activated Nox2 
complex, and mutant SOD1 locks Rac1 into its active state, with resultant prolongation of 
ROS production (27). Nox2 expression is increased in mSOD1 mice and human ALS, and 
survival of SOD1-G93A mice is extended by knock-out of either Nox1 or Nox2. The 
transcription factor Nrf2 (nuclear erythroid-2-related factor2) is a master regulator of the 
anti-oxidant response and responds to oxidative stress by binding and up-regulating anti-
oxidant response element genes. Recent evidence has emerged that Nrf2-ARE signalling 
may be dysregulated in models of SOD1-related ALS and in the CNS of ALS patients (28).
A meta-analysis of therapeutic interventions in the mSOD1 mice up to 2007 concluded that 
anti-oxidant therapies were the class of drug most effective at improving survival (29). In 
human ALS, anti-oxidants have not yet shown benefit, although the reported trials have 
Turner et al. Page 4
Amyotroph Lateral Scler Frontotemporal Degener. Author manuscript; available in PMC 2015 January 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
often been of suboptimal design, and new in vitro screening methods may be able to 
generate future candidates (30).
Mitochondrial dysfunction
Mitochondria are critical for cell survival, acting as an energy source of the cell, buffering 
intracellular calcium, and regulating apoptosis. Damage to mitochondria selectively within 
tissues affected in ALS has been widely observed, especially in inherited disease caused by 
mutations in SOD1. Mitochondrial abnormalities may be a trigger or a consequence of the 
neurodegenerative process and the precise mechanisms remain uncertain (31, 32). Mutant 
SOD1 is localized in mitochondria, and accumulates on the outer membrane and inside the 
intermembrane space (33). Mutant SOD1 and other mutant proteins, such as TDP-43, may 
cause mitochondrial dysfunction by affecting the expression of mitochondrial proteins 
involved in energy metabolism. Mitochondria can also be affected by external SOD1 
interfering with signalling and transport of the organelles. Key surface components inhibited 
by misfolded mSOD1 include the following:
• the voltage-dependent anion channel (VDAC1), the conductance of which is 
inhibited (34);
• the translocase of the outer membrane (TOM) transport complex, which is 
responsible for the import into mitochondria of over 1000 proteins made in the 
cytoplasm (35);
• Bcl2, an anti-apoptotic protein normally associated with mitochondria (36).
As a consequence of mSOD1 damage, mitochondria are non-uniformly distributed along 
axons of motor neurons (37).
The selective association of mSOD1 with mitochondria in cells of affected tissues remains 
uncertain, as is whether differences in mitochondria or cytoplasmic components (e.g. 
chaperones) may be responsible for tissue-specific abnormalities of protein folding. Drugs 
targeting mitochondrial properties (e.g. calcium conductance, biogenesis, fission, fusion, or 
transport) might provide therapeutic benefit. Mitochondrial modulators are a new class of 
potential therapeutic. Olesoxime promotes survival of mutant motor neurons in vitro (38), 
possibly by binding to the mitochondria, targeting VDAC and the benzodiazepine receptor. 
However, a recent human phase III study of olesoxime in ALS proved negative. 
Dexpramipexole is a mitochondrial ‘ membrane stabilizer’  (39, 40), but a human phase III 
study in ALS also proved negative.
Neuroinflammation
Inflammatory mechanisms and immune reactivity are hypothesized to play a role in the 
pathogenesis of ALS (41). In experimental models, the progression of ALS has been linked 
to microglial cell/ macrophage activation in the spinal cord. Studies in patients with ALS 
have found elevated markers of inflammation (CRP, interleukin-6 and 13, macrophage 
chemotactic protein-1 (MCP-1)) (42). Levels of MCP-1 and other chemokines have also 
been detected in the CSF of ALS patients (43, 44). Such proteins may contribute to the 
amplification or possibly initiation of inflammation during ALS. Additionally, systemic 
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macrophage activation and alteration of macrophage surface markers have been linked to 
disease progression (45). Donor macrophages were present at sites of neuron loss after bone 
marrow transplantation, suggesting an ongoing migration of blood monocytes in patients 
with ALS (46). Macrophage activation markers in ALS blood are similar to those identified 
in the blood of patients with AIDS dementia where macrophages invading the CNS have 
been proven to induce neurodegeneration. Studies with Neuraltus Pharmaceuticals NP001, a 
small molecule regulator of macrophage activation in the SOD1 mouse model, demonstrated 
longer survival compared with controls (19 days, p= 0.01) and slowing of the decline in 
neurological score. Phase II studies in humans are currently underway.
Altered energy metabolism
Studies in animal models have convincingly demonstrated that whole body energy 
physiology is impaired in ALS, and that this contributes to motor neuron degeneration (47, 
48). In patients, much of the evidence that similar events occur is correlative. Most 
importantly, body mass index and overall nutritional status at disease onset appear to be 
strong predictors of survival of patients (49, 50). Circulating blood lipids are positively 
correlated with survival (51, 52) or functional status (53). Whether these statistical 
associations might translate into a sensitive and specific biomarker awaits further 
investigation. Multiple confounders might blur the sensitivity and specificity of such 
markers. first, dysphagia as a consequence of bulbar involvement, has a strong impact on 
nutritional status, and is on its own a sign of poorer prognosis. Secondly, impaired glucose 
tolerance has been observed in ALS patients, and it is unknown whether abnormalities in 
glucose metabolism influence survival in ALS. finally, regional and national dietary 
specificities are very likely to have strong influence on blood lipids and nutrition, and may 
confound the observed effects. Metabolomic studies in the blood of ALS patients and animal 
models might delineate a core set of metabolites that could be useful as biomarkers. A recent 
metabolomics study identified altered metabolites indicative of disrupted mitochondrial 
function and increased carbohydrate and lipid metabolism in ALS patients (54). 
Alternatively, imaging methods, in particular MRI of adipose tissues (55), DEXA-scan or 
CT may help to determine whether energy stores provide a biomarker related to energy 
metabolism.
Disease models
For human neurodegenerative diseases it is not currently possible to study cellular 
pathological processes in real time, or safely and repeatedly remove tissue for analysis. The 
ability to study cellular molecular processes, identify key pathways for intervention, and 
assess multiple candidate therapies over short periods of time, depends on the development 
of disease models. The ability to express both wild-type and mutant human genes in non-
human cells and transgenic animals has provided a variety of possibilities for modelling 
many neurodegenerative disorders, including ALS (56, 57). The discovery of linkage to the 
SOD1 gene of some cases of familial ALS led rapidly to the creation of an overexpressing 
mutant SOD1 transgenic mouse (58). This and other models are summarized in Table II. 
Such models do not, as yet, capture pathogenesis at a systems level, and no one model has 
yet been able to reproduce all of the pathological and behavioural features of ALS. 
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Nonetheless, they have provided a valuable platform for testing many of the pathogenic 
hypotheses outlined earlier in this article, with hope for the future development of assays for 
high-throughput screening of therapeutic candidates.
Induced pluripotent stem cells
The generation of motor neurons from induced pluripotent stem cells (iPSCs), in turn 
derived from the skin fibroblasts of ALS patients (59), has marked a major advance in 
modelling pathogenesis in ALS, with potential for high-throughput therapeutic assessments. 
Encapsulated by the phrase ‘ disease in a dish’ , iPSCs carrying the TDP-43 ‘ M337V’  
mutation have already been shown to reproduce several key aspects of TDP-43-related 
proteinopathies, including aggregate formation and reduced cell survival (60). The ability to 
generate not only motor neurons but also other non-neuronal cell types (including astrocytes, 
oligodendrocytes, microglia), will allow for versatility in teasing out cell-specific 
contributions to disease development. iPSCs from patients with familial ALS have already 
been made available to researchers at the NINDS Repository, thus allowing for the study of 
ALS arising from numerous SOD1, FUS, and FIG4 mutations.
However, a number of challenges remain with regard to human iPSC uses for investigation 
into ALS biology. Currently, the long periods of time required to generate human neural 
cells (for example, astrocytes) results in significant expense and often complex experimental 
paradigms. Because iPSCs are derived from individual patients, careful assessment of the 
sample sizes studied should be considered before broad conclusions can be made about 
disease from a single iPSC source. The impact of the patients'  age on the resulting iPSC 
remains unclear. If used to screen for potentially relevant ALS drug targets, standardization 
of cell lines across laboratories will be important for validation of drug effects. Future aims 
include the development of more complex integrated structures, for example the 
neuromuscular junction using muscle and neuronal cell cocultures (61).
Despite these challenges, it is likely that more efficient derivation of iPSC will be 
developed, thus shortening the time and expense currently associated with creating iPSC 
lines. As sources of iPSC become more readily available to the research community, 
investigators with a wide range of research interests will be able to draw on a range of ALS 
genotypes and phenotypes thus allowing for the identification of new ALS relevant disease 
targets for therapeutics.
Tissue and fluid biomarker sources
Biofluids
The range of human biofluids useful in proteomic studies to identify an ALS biomarker 
‘ signature’ , includes CSF, blood, urine, and saliva (62). CSF is an excellent biofluid for 
biomarker discovery due to its approximation to the cells and brain and spinal cord regions 
exhibiting cell death during ALS. Blood, while more accessible, has greater protein 
complexity with greatly reduced concentrations, compared to CSF, of those proteins 
fundamentally involved in neuronal function.
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During the past decade there has been a large increase in the number of ALS biomarker 
studies using CSF as well as blood (22). Most of these studies have examined changes of 
individual proteins in the CSF of ALS versus healthy control or other neurologic disease 
subjects, typically using a gel-based system or ELISA (63). However, most are limited by 
the number of samples used in the analysis, choice of control subjects, and typically the lack 
of verification in a separate cohort of patients. A number of more recent studies have used 
mass spectrometry or cytokine profiling to identify panels of candidate protein biomarkers 
in the CSF (43,64). Metabolomic approaches have been used to explore metabolic 
differences between ALS and control subjects in CSF and serum (54, 65 – 67). Early 
changes in patient metabolism and protein levels or post-translational modifications offer a 
means to both identify ALS at an early stage and to develop biomarkers to follow during 
disease progression.
At present, CSF candidate biomarkers in ALS can be grouped into those that reflect 
neuronal loss and those indicative of neuroinflammatory (glial) processes. For the former, 
neurofilaments have been the most reproducible (68 – 70). CSF TDP-43 appears to fall with 
disease progression in typical ALS (71), with lower values found in cases of ALS-FTD (72). 
The significance of finding reduced CSF transthyretin and cystatin C in ALS is uncertain 
(64). The latter is the essential constituent of the ‘ pathognomonic’  Bunina body inclusion 
seen histopathologically in ALS and has been detected at increased levels in ALS plasma 
(73).
While several molecules linked to neuroinflammatory pathways have been reported as 
increased in ALS patient CSF, each has limited sensitivity in isolation and many studies 
have not been reproduced. A panel of cytokines, specifically interleukins 2, 6, 10, 15 and 
granulocyte-monocyte colony stimulating factor (GM-CSF) was nearly 90% accurate in 
distinguishing ALS patients from healthy controls (43). Other studies have also supported 
the concept of combining markers to improve accuracy, most recently the ratio of CSF 
phosphorylated neurofilament-heavy chain and complement C3, achieving even higher 
accuracy (74). CSF based biomarkers may be useful to aid in the diagnosis of ALS, but may 
have better applications in monitoring drug effects in clinical trials and as prognostic 
indicators of disease (73,75). Further studies, involving samples from mimic disorders rather 
than healthy controls, and serial samples from ALS patients, are required to validate the 
candidate diagnostic biomarkers and fully explore their utility in therapeutic trials. An 
important step has been to both recognize the potential variability in sample quality due to 
differences in acquisition and storage (76), and to establish international consensus on 
standard operating procedures (77).
Muscle
Skeletal muscle may represent a valuable source of biomarkers in ALS. This tissue is one of 
the most severely affected by the disease, with progressive denervation and atrophy, and it is 
easily accessible to biopsy. The only muscle biomarker that has been tested prospectively is 
the axon repellant Nogo-A. Nogo-A is strongly expressed in ALS muscles, is correlated with 
ALSFRS and prospectively identifies patients affected with lower motor neuron disease that 
will progress to ALS (78–80). However, the specificity of this increased expression has been 
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questioned. A combination of biomarkers might solve the problem of specificity. Muscle 
transcriptome analyses have identified a number of potential candidates correlated with 
disease severity (81). There are two potential limitations of muscle biomarkers. first, muscle 
biopsy is invasive and as a consequence longitudinal studies are very difficult. Secondly, 
muscle beds are very differentially involved among patients. The different sites of onset, as 
well as the heterogenous spreading, make it difficult to standardize the choice of the site of 
muscle biopsy. In this respect, the future of muscle biomarkers might be to identify a set of 
muscle derived proteins or peptides that enter the circulation. Such muscle-derived blood 
biomarkers could be useful tools to evaluate disease progression and severity in ALS 
patients in a manner similar to creatine kinase for myopathies.
Skin
The skin is an acknowledged part of the disease process in ALS, both in experimental 
models (82) and humans (83 – 85). Because this organ is easily accessible and at least some 
of the biochemical alterations are related to findings in the CNS (82, 83), the skin is a 
principal resource of biomarkers for diagnosis, staging, and evaluation of therapy. The most 
striking finding is an apparently selective elevation of the MMP-9 in the skin and spinal cord 
of experimental animals and in human skin and the CSF (82, 83). These findings are 
consistent with previous observations of increased collagen degradation, in particular 
collagen types I and IV, in the skin of ALS patients (84). The pathogenic steps responsible 
for these observations remain to be elucidated; however, free radical damage and 
inflammation are possible mechanisms. A further discovery was that small distal epidermal 
nerve fibers are affected in ALS (85), indicating the presence of a small fiber neuropathy. 
The pattern of changes reflects the concept of a distal axonopathy and paves the way for 
mechanistic studies of cytoskeletal alterations and axonal transport.
Post mortem tissues
While post mortem spinal cord, brain or muscle tissue may not provide the optimal resource 
for biomarker discovery efforts, they are especially important to help identify the cell types 
that express each candidate biomarker, as well as their relationship to the pathophysiology 
of the human disease. Increased efforts to collect ALS and appropriate control post mortem 
tissues become more crucial as the multitude of candidate biomarkers identified in the above 
mentioned biofluids and tissue biopsies will require proper characterization and correlation 
to ALS pathology. In addition, recent studies have shown that neural progenitor cells can be 
cultured from ALS post mortem tissues and used to generate astrocytes to investigate 
astrocyte derived cell signalling that influences motor neuron survival (86). Given the low 
numbers of banked ALS tissues at any one site, standardized collection and storage 
procedures for ALS post mortem tissues must be established to permit use of tissues 
obtained across multiple sites.
Neurophysiology biomarker sources
EMG and MUNE
Neurophysiological testing has been an important component of the diagnostic evaluation of 
patients with motor neuron disease since the demonstration that axon loss and consequent 
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reinnervation could be measured using electromyography (EMG) (87). While classical EMG 
and nerve conduction studies are still incorporated into diagnostic criteria for ALS (El 
Escorial), these techniques have not proved effective in monitoring disease progression or 
assessing effects of treatment. Motor unit number estimation (MUNE) is a tool that was 
developed for this purpose. The technique and theoretical basis for MUNE is quite simple; a 
maximum response amplitude, which is generated by activation of all motor units in the 
muscle, is recorded, from which an estimate of individual motor unit number is generated by 
dividing the maximum response amplitude by an estimate of single motor unit amplitude. 
Many techniques for estimating the average amplitude of single motor units have been 
suggested; most have been limited by sampling bias, and lack of reproducibility (88).
Recently, a modification of earlier described techniques was introduced and studied in a 
natural history study of patients with ALS (89). Multipoint incremental MUNE was found to 
have excellent test-retest reliability, and to decline monotonically in ALS faster than other 
measures traditionally used in ALS clinical trials. The technique can be well standardized, is 
performed briefly with good patient tolerance, and has a low computational burden. Using 
rate of decline as well as variability, hypothetical power analyses suggested that this 
measure might reduce both sample size and study duration in phase II trials. Other new 
MUNE methods, including MUNIX (90) and Bayseian MUNE (91,92) are also being 
developed. While no physiological method of motor unit number estimation has been 
validated against anatomical motor unit counts, their use as potential endpoints in clinical 
trials shows great promise.
Transcranial magnetic stimulation
ALS is diagnosed clinically by the presence of both UMN and LMN damage. While LMN 
abnormalities can be confirmed objectively using peripheral electrodiagnostic methods, 
UMN findings lack comparable established objective markers. Transcranial magnetic 
stimulation (TMS) is a neurophysiological test that measures UMN functional integrity, and 
can detect abnormalities when there are no clinical UMN signs. TMS works by evoking 
compound motor potentials (MEP) using non-invasive magnetic stimulation of the motor 
cortex through activation of both UMN and LMN pathways. It is used to study the 
conductivity and excitability of the corticospinal system. As potential physiological 
biomarkers, TMS measurements reflect the functional integrity of the UMN (93).
Single pulse TMS is a well established diagnostic and clinical research tool, although results 
vary widely between medical centers. However, if individual laboratories establish their own 
normative data, subjects can be tested in a consistent, reliable fashion. TMS recordings 
include measurements of motor threshold, central motor conduction time, and MEP 
amplitudes, all of which may be abnormal in ALS (94). TMS also can be delivered in paired 
pulses, or as repetitive trains of stimulation for investigating human brain function, 
transiently stimulating or inhibiting different cortical areas (95, 96).
TMS biomarkers, particularly single pulse evoked TMS amplitude, have been used to 
objectively discriminate ALS from controls and assess the progression of ALS (97 – 99). 
TMS can reveal subtle subclinical UMN dysfunction to help make the diagnosis of ALS as 
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well as clarify the relationship between ALS and its variants (100), including progressive 
muscular atrophy where there may be subclinical UMN changes.
Electrical impedance myography
Electrical impedance myography (EIM) is a technique in which a high-frequency, low-
intensity electrical current is applied to a localized area of muscle and the consequent 
surface voltages measured (101). Unlike standard electromyography, in which the intrinsic 
electrical activity of muscle is measured, EIM assesses the integrity and structure of the 
muscle. An initial, single-center study demonstrated EIM' s potential power at measuring 
disease progression in this disease (102). Recently, a second multicenter study compared 
EIM directly to the ALSFRS-R, MUNE, and handheld dynamometry (103). EIM 
outperformed the other measures in terms of its ability to detect deterioration. For example, 
based on these data, a study that would require 220 subjects using the ALSFRS-R would 
have the same power as one with only 95 using EIM. Studies in ALS rats have similarly 
showed a strong correlation to the rate of change in EIM and the animal' s length of survival, 
as well as to MUNE (104). The methodology is also being applied in the first North 
American study of neural stem cells in ALS (105). One advantage of EIM over most other 
modalities is its ability to assess a variety of muscles and to measure specifically that area of 
the body where the disease is progressing most rapidly. Measurement of other muscles not 
routinely studied but which might provide valuable data, such as paraspinal muscles and the 
tongue, is also possible. Current efforts are geared toward further refining the technique for 
easy use and making it widely available (106).
Neuroimaging biomarker sources
MRI has a major role in the exclusion of cerebral, and particularly spinal mimics of ALS 
(107). However, neuroimaging is also at the forefront of advances in the understanding of in 
vivo cerebral disease mechanisms in ALS, including rodent models (108), with the 
identification of multiple candidate biomarkers as a result (109).
Radionuclide imaging
Single photon emission computed tomography (SPECT) is a practical and potentially widely 
applicable form of radionuclide imaging. It was at the forefront of the recognition of a 
clinical, pathological and, most recently, genetic continuum between ALS and 
frontotemporal dementia (FTD) (110). Positron emission tomography (PET) has greater 
resolution than SPECT but is limited by the availability of experienced facilities. Pivotal 
‘ activation’  PET studies, using tracers sensitive to blood flow and metabolism (e.g. 
radiolabelled water and flurodeoxyglucose, FDG), provided in vivo evidence for a consistent 
extramotor cerebral pathology in ALS (111). Subsequently, ‘ ligand’  PET has been used to 
identify specific cerebral neuronal receptor changes in ALS. Such studies have provided 
evidence for a loss of cortical inhibition (112) that might influence progression rate (113), 
widespread microglial activation (114), and a striking reduction in serotonin-1A receptor 
binding (115), similar to changes seen in FTD (116). The future value of PET in ALS will 
depend upon the development of ligands with relevance to pathogenic hypotheses, e.g. 
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glutamate receptors, and more specific neuroinflammatory or protein markers, e.g. TDP-43 
(the challenge of intracellular penetration notwithstanding).
Magnetic resonance imaging (MRI)
The observation of corticospinal tract hyperintensity lacks sensitivity and specificity for the 
diagnosis of ALS. Routine clinical structural imaging of the brain has limited value as a 
source of biomarkers in ALS, and only through advanced analysis methods (117). The 
acquisition of high-resolution 3D T1-weighted images and the development of novel pulse 
sequences such as diffusion tensor imaging and functional MRI have greatest potential in 
this regard, and would ultimately be feasible to perform within the clinical environment 
(118).
Macroscopic atrophy of the motor cortex is not a consistent observation in ALS, although 
prominent in those with PLS. Sophisticated analysis of 3D T1-weighted structural images 
acquired in 3D, known as voxel-based morphometry (VBM), can reveal subtle changes in 
regional cerebral tissue. Several VBM studies have been performed in ALS, and meta-
analysis showed the right precentral gyrus as consistently altered (119). Surface-based 
morphometry allows assessment of cortical thickness, and a study in ALS confirmed not 
only primary motor, but also extramotor, temporal cortical thinning in faster progressors 
(120).
Post mortem histopathological study first demonstrated widespread cerebral white matter 
tract damage in ALS (121) and this can now be detected non-invasively using diffusion 
tensor imaging (DTI). This advanced MRI technique is sensitive to the movement of water, 
normally directionally confined within neuronal tracts. The two main quantitative measures 
of loss of neuronal tract integrity are reduced fractional anisotropy (FA) and increased mean 
diffusivity. Related parameters such as increased radial diffusivity may specifically reflect 
secondary demyelination of tracts in ALS. DTI studies have shown consistently reduced FA 
in the corticospinal tract, particularly within the posterior limb of the internal capsule (PLIC) 
(122) and corpus callosum (123) of ALS patients. Targeted FA measurement at the PLIC 
may provide prognostic information (124). DTI measures may, however, be insufficiently 
sensitive to longitudinal change over less than six months (125), nor have sufficient 
discriminatory power as an isolated measurement (126).
MRI is unsurpassed in its spatial resolution of cerebral functional activity achieved non-
invasively. Blood oxygenation level-dependent (BOLD) functional MRI (fMRI) studies of 
motor tasks in ALS patients confirmed the widened region of activation observed in PET 
studies. More recently, however, it is the study of the ‘ resting state’  that provides novel 
insight into ALS as a ‘ system failure’ . Resting-state fMRI (R-fMRI) has demonstrated 
increased functional connectivity within the damaged ALS cortical network, with possible 
implications in relation to cortical inhibitory influences (127). The combination of structural 
and functional MRI measures in this study also provided much better separation of patients 
from healthy age-matched controls.
Magnetic resonance spectroscopy (MRS) is an application of MRI that permits 
quantification of cerebral tissue metabolites. It has consistently demonstrated reduced N-
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acetylaspartate ratios (a non-specific marker of neuronal loss) in the motor cortex of ALS 
patients, and high-field studies also suggest a specific loss of GABA-ergic influence (128). 
Recent studies applied to the cervical spinal cord of pre-symptomatic carriers of 
pathological SOD1 gene mutations demonstrated metabolite changes more consistent with 
affected ALS patients rather than healthy non-gene carriers (129), suggesting that MRS may 
be particularly sensitive to pre-clinical changes. This offers the hope of capturing the very 
earliest events in individuals carrying genetic abnormalities associated with the development 
of ALS, with the possibility of wider translation to sporadic cases.
The challenge for neuroimaging biomarker candidates is to move beyond results based on 
group averages, to individual measurements. It seems likely that this will require multiple 
parameters. Further longitudinal studies are needed to assess the sensitivity of multimodal 
MRI to disease activity compared to clinical assessments such as ALSFRS.
Concluding remarks
Major advances in the understanding of the pathobiology of ALS have occurred over the last 
two decades with developments in molecular biology, immunocytochemistry, 
neurophysiology and neuroimaging, and the recognition of overlap with some forms of 
FTD. It seems increasingly likely that there are multiple, possibly more discrete, pathways 
converging on motor neuron death. While recent discoveries in relation to RNA biology hint 
at a massively under-estimated level of pathological complexity in ALS, the common theme 
of misfolded protein inclusions across the range of neurodegenerative disorders brings the 
hope of a common strategy for the treatment of pre-aggregation events (130) and for 
common biomarker development. Biomarker candidates are emerging with the potential to 
refine the diagnosis, stratify patients prognostically, and facilitate therapeutic development. 
A key aim for further biomarker development, beyond validation across multiple centers, is 
the routine incorporation of biomarker measurement into future clinical trials.
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Table I
Types of biomarker in ALS, their value and the current gold standards.
Biomarker type Value Current benchmarks
Diagnostic Initiate therapy earlier;Exclude ALS
Neurological history & examination
Electromyography (Revised El Escorial/Awaji 
criteria) 131
Prognostic Identify patterns of progression:
1 Improved stratification in therapeutic trials
2 Timely intervention and optimal care
e.g. gastrostomy, non-invasive ventilation, 
cognitive support
Diagnostic latency
Neurological evaluation (e.g. clinical phenotypes)
Cox modelling of clinical variables 132,133
Monitoring Identify ineffective drugs earlier Revised ALS Functional Rating Score 134
(Electrical impedance myography emergent 102 )
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Table II
Models of ALS pathology, and their key features.
Model Specifics ALS-like pathology Potentially relevant physical features Advantages Disadvantages Key references
Yeast Saccharomyces cerevisiae 
SOD1, TARDBP, or FUS-
related transgenics;
Also used as a screening 
model for novel RNA-
binding-related genes
Mutant SOD1 disrupts mitochondrial 
homoeostasis;
Recapitulation of TDP-43 & FUS 
aggregation with identification of 
modulators
NA Readily available, low 
maintenance; homologous 
basic cellular structures to 
humans; non-animal; rapid 
turnover; high throughput
Cellular toxicity arising 
simply from over-
expression of human 
proteins; facultative aerobe 
unlike human cells
135-137
Worm Caenorhabditis elegans 
SOD1, TARDBP, or FUS-
related transgenics
Increased sensitivity to oxidative stress 
in presence of mutant SOD1, with 
aggregate formation;
Aggregates of mutant TDP-43 & FUS
Progressive ‘ incoordination’  
& paralysis over hours-days in 
overexpressing mutant 
(especially phosphorylated) > 
wild-type TDP-43 & FUS 
(and only mutant SOD1) 
worms
Readily available, low 
maintenance; homologous 
basic neuromuscular 
structures to humans
Variable effects and limited 
human clinical similarity
Reviewed in56 See 
also138,139
Fruit fly Drosophlia melanogaster 
SOD1, TARDBP, or FUS-
related transgenics
Variable effects of both wild-type and 
mutant TDP-43 & FUS on aggregate 
formation, dendritic branching, and 
NMJ dysfunction depending on tissue 
expression
Variable effects of both wild-
type and mutant SOD1, 
TDP-43 & FUS on larval 
locomotor function depending 
on tissue expression
Readily available, low 
maintenance; homologous 
basic neuromuscular 
structures to humans; short 
life cycle
Variable effects and limited 
human clinical similarity
Reviewed in56 See 
also140-143
Zebrafish Danio rerio SOD1, 
TARDBP, or FUS-related 
transgenics
Mutant SOD1 linked to MN loss and 
dysmorphic NMJs;
Mutant TDP-43 linked to decreased 
motor axon length and branching;
Mutant FUS linked to cytoplasmic 
inclusions
Mutant SOD1 associated with 
motor abnormalities and 
muscle atrophy
Readily available, low 
maintenance; homologous 
basic neuromuscular 
structures to humans; short 
life cycle
Variable effects and limited 
human clinical similarity
Reviewed in56 See 
also144,145
Rodent Mus musculus Է Rattus 
norvegicus SOD1 or 
TARDBP-related 
transgenics
Mutant SOD1 linked to gliosis, 
ubiquitinated SOD1 inclusions, 
mitochondrial vacuolation, axonal and 
MN loss;
WT and mutant TDP-43 more variably 
linked to cellular aggregates or MN 
loss
Progressive locomotor 
abnormalities with hind-limb 
weakness and muscle wasting 
from Ԉ3 months
WT and mutant TDP-43 less 
consistently linked to any 
motor abnormalities and 
muscle atrophy
Consistent motor 
phenotype; readily 
available, low 
maintenance; homologous 
basic neuromuscular 
structures to humans; short 
life cycle
Costly infrastructure; some 
ethical concerns
Poor translation of 
therapeutic response in 
SOD1 mouse to human 
studies so far
TDP-43 models show 
limited motor phenotype
Reviewed in56,146
Dog ‘ Canine degenerative 
myelopathy’ :
Pembroke Welsh corgi, 
Boxer, Rhodesian 
ridgeback, German 
Shepherd, & Chesapeake 
Bay retriever all 
homozygous for SOD1 
‘ E40K’  missense mutation
Lateral cord white matter myelin and 
axonal loss;
Neuronal cytoplasmic inclusions 
binding anti-SOD1 antibodies
Adult-onset progressive 
spastic myelopathy affecting 
pelvic girdle, leading to 
eventual flaccid quadriparesis
Similar to human SOD1-
related ALS in being a 
delayed adult-onset 
disorder
Ethical concerns, 
availablity and 
infrastructure issues; long 
latency to symptoms; 
limited relevance to non- 
SOD1-related ALS
147
Monkey Macaca fascicularis over-
expressing human TDP-43 
Cytoplasmic mislocalization of 
TDP-43; cystatin-C positive 
Aggregates
Progressive motor weakness 
of distal upper limbs with 
fasciculation and wasting
Closest species to humans 
physically and 
behaviourally
Major ethical concerns and 
infrastructure issues; 
limited relevance to 
148
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Model Specifics ALS-like pathology Potentially relevant physical features Advantages Disadvantages Key references
via adenovirus to cervical cord 
via adenovirus to cervical cord
‘ slowly-developing’  human 
ALS
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